Shilpa Medicare Ltd

Shilpa Medicare Share Pledge

The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.

Shilpa Medicare Other Announcement

Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.

Shilpa Medicare Business Update

Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.

Shilpa Medicare Regulatory Approval

Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.

Shilpa Medicare Annual General Meeting

Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.

Shilpa Medicare Insolvency Petition

NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.

Value

₹2.18 Cr

Shilpa Medicare Investor Presentation: Key Takeaways

Shilpa Medicare reported record Q1FY27 revenue of INR 469cr, up 43% YoY, with EBITDA margins hitting 30%. Strategy focuses on high-margin CDMO, Biologics, and complex formulations.

Shilpa Medicare Q1 FY27 Results: Net Profit ₹100.9 Cr, Up 115.1% YoY

Shilpa Medicare Ltd reported revenue from operations of ₹465.8 Cr (+44.9% YoY) and net profit of ₹100.9 Cr (+115.1% YoY) for Q1 FY27.

Key figure

Net profit ₹100.9 Cr · +115.1% YoY

Shilpa Medicare Earnings Call Transcript: Key Takeaways

Shilpa Medicare delivered a robust Q4 performance with revenue growing 30% YoY, driven by API and formulation scale-ups, but remains heavily dependent on lumpy licensing income and future global clinical trial successes.